The Central Social Insurance Medical Council, a key Japanese reimbursement policy panel better known as Chuikyo, approved an outline of…
HOME > BUSINESS
BUSINESS
- Daiichi Sankyo Unable to Ship 2.36 million Vials of Flu Vaccine Due to Virus Contamination
September 26, 2011
- OncoTherapy To Receive Milestone Payment following Submission of PI Clinical Trial Certificate
September 26, 2011
- Shanghai Genomics Receives New Drug Certificate for the Treatment of IPF in China
September 26, 2011
- Astellas: OAB Treatment Betanis Tablets
September 26, 2011
- Ono/Astellas: Once-Every-Four-Weeks Formulation of Recalbon, Bonoteo
September 26, 2011
- MTPC, Janssen Pharma Launch RA Treatment Simponi
September 26, 2011
- Vibativ Approved in Europe for Treatment of Nosocomial Pneumonia: Astellas
September 26, 2011
- 60% of License Agreements Cancelled Due to Changes in Partners’ Business Strategy
September 26, 2011
- Daiichi Sankyo Announces Delay in Flu Vaccine Shipment Due to Possible Contamination
September 26, 2011
- Ajinomoto Files Suit over Actonel Generic Seeking Suspension of Sales
September 26, 2011
- Trans Genic Files Patent Application for Antibody against Novel Lung Cancer Marker
September 26, 2011
- US FDA Completes Review of Protocol for PIII Trial of Collategene: AnGes MG
September 26, 2011
- Takeda Aiming to Make Comeback in Diabetes Market
September 25, 2011
- Novartis Grows 7% Driven by New Products: President Mitani
September 22, 2011
- PIII Trial for Brain Function Imaging Agent Starts: Nihon Medi-Physics
September 21, 2011
- Nichi-Iko to Postpone M&A of Nichi-iko Pharma Factory Until June 2012
September 21, 2011
- Kaken President Onuma Targets ¥20 Billion in Operating Profits in 2015
September 21, 2011
- Kowa Yakuhin Sets Up Private Electric Generators as Part of Disaster Measures
September 20, 2011
- Sitagliptin Receives Approval for Use in Combination with Insulin: MSD, Ono
September 20, 2011
- CellCept Obtains Approval for Additional Pediatric Dosage: Chugai
September 20, 2011
ページ
As many as 47 new drug candidates are expected to win approval or secure NHI price listing in Japan in…
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…